Therapeutic Response

PD-L1 >= 1% status confers therapeutic sensitivity to Ipilimumab in combination with Nivolumab in patients with Esophageal Squamous Cell Carcinoma.

Statements

Source and description
Opdivo (nivolumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression >= 1%.
Yervoy (ipilimumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma with tumor cell PD-L1 expression >= 1%.